Cargando…
Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging
BACKGROUND: Tissue imaging of treatment-induced metabolic changes is useful for optimizing cancer therapies, but commonly used methods require trade-offs between assay sensitivity and spatial resolution. Nanostructure-Initiator Mass Spectrometry imaging (NIMS) permits quantitative co-localization of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834492/ https://www.ncbi.nlm.nih.gov/pubmed/24280026 http://dx.doi.org/10.1186/2049-3002-1-4 |
_version_ | 1782292001035649024 |
---|---|
author | O’Brien, Peter J Lee, Michelle Spilker, Mary E Zhang, Cathy C Yan, Zhengming Nichols, Timothy C Li, Wenlin Johnson, Caroline H Patti, Gary J Siuzdak, Gary |
author_facet | O’Brien, Peter J Lee, Michelle Spilker, Mary E Zhang, Cathy C Yan, Zhengming Nichols, Timothy C Li, Wenlin Johnson, Caroline H Patti, Gary J Siuzdak, Gary |
author_sort | O’Brien, Peter J |
collection | PubMed |
description | BACKGROUND: Tissue imaging of treatment-induced metabolic changes is useful for optimizing cancer therapies, but commonly used methods require trade-offs between assay sensitivity and spatial resolution. Nanostructure-Initiator Mass Spectrometry imaging (NIMS) permits quantitative co-localization of drugs and treatment response biomarkers in cells and tissues with relatively high resolution. The present feasibility studies use NIMS to monitor phosphorylation of 3(′)-deoxy-3(′)-fluorothymidine (FLT) to FLT-MP in lymphoma cells and solid tumors as an indicator of drug exposure and pharmacodynamic responses. METHODS: NIMS analytical sensitivity and spatial resolution were examined in cultured Burkitt’s lymphoma cells treated briefly with Rapamycin or FLT. Sample aliquots were dispersed on NIMS surfaces for single cell imaging and metabolic profiling, or extracted in parallel for LC-MS/MS analysis. Docetaxel-induced changes in FLT metabolism were also monitored in tissues and tissue extracts from mice bearing drug-sensitive tumor xenografts. To correct for variations in FLT disposition, the ratio of FLT-MP to FLT was used as a measure of TK1 thymidine kinase activity in NIMS images. TK1 and tumor-specific luciferase were measured in adjacent tissue sections using immuno-fluorescence microscopy. RESULTS: NIMS and LC-MS/MS yielded consistent results. FLT, FLT-MP, and Rapamycin were readily detected at the single cell level using NIMS. Rapid changes in endogenous metabolism were detected in drug-treated cells, and rapid accumulation of FLT-MP was seen in most, but not all imaged cells. FLT-MP accumulation in xenograft tumors was shown to be sensitive to Docetaxel treatment, and TK1 immunoreactivity co-localized with tumor-specific antigens in xenograft tumors, supporting a role for xenograft-derived TK1 activity in tumor FLT metabolism. CONCLUSIONS: NIMS is suitable for monitoring drug exposure and metabolite biotransformation with essentially single cell resolution, and provides new spatial and functional dimensions to studies of cancer metabolism without the need for radiotracers or tissue extraction. These findings should prove useful for in vitro and pre-clinical studies of cancer metabolism, and aid the optimization of metabolism-based cancer therapies and diagnostics. |
format | Online Article Text |
id | pubmed-3834492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38344922013-11-21 Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging O’Brien, Peter J Lee, Michelle Spilker, Mary E Zhang, Cathy C Yan, Zhengming Nichols, Timothy C Li, Wenlin Johnson, Caroline H Patti, Gary J Siuzdak, Gary Cancer Metab Methodology BACKGROUND: Tissue imaging of treatment-induced metabolic changes is useful for optimizing cancer therapies, but commonly used methods require trade-offs between assay sensitivity and spatial resolution. Nanostructure-Initiator Mass Spectrometry imaging (NIMS) permits quantitative co-localization of drugs and treatment response biomarkers in cells and tissues with relatively high resolution. The present feasibility studies use NIMS to monitor phosphorylation of 3(′)-deoxy-3(′)-fluorothymidine (FLT) to FLT-MP in lymphoma cells and solid tumors as an indicator of drug exposure and pharmacodynamic responses. METHODS: NIMS analytical sensitivity and spatial resolution were examined in cultured Burkitt’s lymphoma cells treated briefly with Rapamycin or FLT. Sample aliquots were dispersed on NIMS surfaces for single cell imaging and metabolic profiling, or extracted in parallel for LC-MS/MS analysis. Docetaxel-induced changes in FLT metabolism were also monitored in tissues and tissue extracts from mice bearing drug-sensitive tumor xenografts. To correct for variations in FLT disposition, the ratio of FLT-MP to FLT was used as a measure of TK1 thymidine kinase activity in NIMS images. TK1 and tumor-specific luciferase were measured in adjacent tissue sections using immuno-fluorescence microscopy. RESULTS: NIMS and LC-MS/MS yielded consistent results. FLT, FLT-MP, and Rapamycin were readily detected at the single cell level using NIMS. Rapid changes in endogenous metabolism were detected in drug-treated cells, and rapid accumulation of FLT-MP was seen in most, but not all imaged cells. FLT-MP accumulation in xenograft tumors was shown to be sensitive to Docetaxel treatment, and TK1 immunoreactivity co-localized with tumor-specific antigens in xenograft tumors, supporting a role for xenograft-derived TK1 activity in tumor FLT metabolism. CONCLUSIONS: NIMS is suitable for monitoring drug exposure and metabolite biotransformation with essentially single cell resolution, and provides new spatial and functional dimensions to studies of cancer metabolism without the need for radiotracers or tissue extraction. These findings should prove useful for in vitro and pre-clinical studies of cancer metabolism, and aid the optimization of metabolism-based cancer therapies and diagnostics. BioMed Central 2013-01-23 /pmc/articles/PMC3834492/ /pubmed/24280026 http://dx.doi.org/10.1186/2049-3002-1-4 Text en Copyright © 2013 O’Brien et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Methodology O’Brien, Peter J Lee, Michelle Spilker, Mary E Zhang, Cathy C Yan, Zhengming Nichols, Timothy C Li, Wenlin Johnson, Caroline H Patti, Gary J Siuzdak, Gary Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging |
title | Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging |
title_full | Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging |
title_fullStr | Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging |
title_full_unstemmed | Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging |
title_short | Monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (NIMS) imaging |
title_sort | monitoring metabolic responses to chemotherapy in single cells and tumors using nanostructure-initiator mass spectrometry (nims) imaging |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834492/ https://www.ncbi.nlm.nih.gov/pubmed/24280026 http://dx.doi.org/10.1186/2049-3002-1-4 |
work_keys_str_mv | AT obrienpeterj monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT leemichelle monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT spilkermarye monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT zhangcathyc monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT yanzhengming monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT nicholstimothyc monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT liwenlin monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT johnsoncarolineh monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT pattigaryj monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging AT siuzdakgary monitoringmetabolicresponsestochemotherapyinsinglecellsandtumorsusingnanostructureinitiatormassspectrometrynimsimaging |